Introduction
============

The most common types of dementia are Alzheimer\'s dementia (AD) and Parkinson\'s disease dementia (PDD), while dementia with Lewy bodies (DLB) is the second most common type of dementia, accounting for 15--20% of the global incidence of dementia ([@b1-etm-0-0-7129]--[@b3-etm-0-0-7129]). PDD and DLB are characterized by accumulation of Lewy bodies in brain cells ([@b4-etm-0-0-7129]). From a clinical and neuropathological perspective, DLB and PDD are similar conditions with the same features, namely dementia, parkinsonism, hallucinations and fluctuations of attention or arousal ([@b5-etm-0-0-7129]). They may be distinguished on the basis of the relative timing of dementia and Parkinsonism. Several meta-analyses have been performed to examine the efficacy and safety of cholinesterase inhibitors and memantine, or each drug separately, on CIND-PD, PDD and DLB ([@b6-etm-0-0-7129]--[@b9-etm-0-0-7129]). The studies reported that cholinesterase inhibitors and memantine improve the global impression, cognitive function, psychiatric symptoms or motor function. They evaluated cognitive function via the use of certain screening tests, including the Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA). To the best of our knowledge, no previous meta-analysis has focused on cognitive domains, including attention, processing speed, executive functions, memory and language. The present study hypothesized that cholinesterase inhibitors and memantine may also improve the patients\' cognitive domains in addition to global cognitive function, which may further prove their efficacy. In addition, falls are a common and severe complication of PD patients and seriously affect their daily safety, prognosis and quality of life ([@b10-etm-0-0-7129]), and thus, the effect of cholinesterase inhibitors and memantine on falls was also investigated.

Materials and methods
=====================

### Search strategy

The Cochrane Library, as well as the Pubmed, Embase and Web of Science databases, were searched for relevant studies on clinical trials on cognitive impairment in Parkinson\'s disease (CIND-PD), PDD or DLB published before July 2018. The search terms were as follows: ('Lewy Body Disease' OR 'DLB' OR 'LBD' OR 'dementia with Lewy bod\*' OR 'Lewy bodies dementia' OR 'Lewy Bodies' OR 'lewy\* bod\*') and {'Parkinson Disease' OR 'parkinson\* disease dement\*' OR 'PDD' OR \['cognit\*' and ('PD' or 'parkinson\*')\] OR 'PD-CIND' OR ('CIND' and 'parkinson\*')} and \['Cholinesterase Inhibitors' OR 'cholinesterase inhibitor\*' OR 'Galantamine' OR 'galantamine' OR 'galanthamine' OR ('reminyl\*' or 'Nivalin\*' or 'Razadyne\*') OR 'donepezil' OR ('Aricept\*' or 'E2020') OR 'rivastigmine' OR ('Exelon\*' or 'SDZ ENA 713') OR ('Memantine' OR 'Namenda' OR 'Ebixa' OR 'Mntine')\].

### Selection criteria

Randomized, placebo-controlled trials that assessed the efficacy of cholinesterase inhibitors in patients with CIND-PD, DLB and PDD were selected for the present meta-analysis. The inclusion criteria were as follows: Patients with PD were included if they fulfilled the UK PD Society Brain Bank clinical diagnostic criteria for PD or clinically definite and probable PD diagnosis ([@b11-etm-0-0-7129]--[@b14-etm-0-0-7129]), and if they subsequently developed dementia, met the Diagnostic and Statistical Manual of Mental Disorders fourth edition/revised fourth edition or the Movement Disorders Society criteria at least 1 year after the onset of PD symptoms ([@b15-etm-0-0-7129]); DLB patients were included if they met the consensus guidelines for the clinical and pathological diagnosis of DLB or revised consensus criteria ([@b16-etm-0-0-7129]).

### Data extraction and quality assessment

Two authors independently selected trials for inclusion in the meta-analysis and extracted information on the study design, patient selection criteria, drug doses, trial durations, primary and secondary outcomes, discontinuations and adverse events in each trial. Disagreements were resolved by discussion with other team members or by contacting the original investigators, who were all sent emails with requests to provide the exact data. For any missing standard deviation data, which were not obtainable from the primary investigators, estimated values calculated using the formula no. 8.5.2.3 in the Cochrane handbook were used in the analysis ([@b17-etm-0-0-7129]). The Cochrane criteria were used to assess risk of bias ([@b18-etm-0-0-7129]), and *Grades* of Recommendation, Assessment, Development and Evaluation (GRADE) Profiler software (version 3.6; Cochrane, London, UK) was used to evaluate the quality of the studies according to the GRADE methods ([@b19-etm-0-0-7129]).

### Statistical analysis

The meta-analysis was performed using RevMan software (version 5.3; Cochrane), employing the inverse variance method. Heterogeneity was assessed using the Chi-squared and I^2^ statistical tests, and considered significant if P\<0.05 and I^2^\>50% was obtained by the former and the latter test, respectively. If I^2^\>50%, a sensitivity analysis was performed to determine the reasons for heterogeneity. In this commonly used sensitivity analysis method, each study included is eliminated one by one, followed by effect-size calculation, or the inclusion criteria are changed or certain types of literature are removed prior to effect volume combination. For continuous data, mean differences (MD) or standardized mean differences (SMD) were used in combination with the effect-size (Hedges\'g) data. For dichotomous data, the risk ratio (RR) was estimated along with associated 95% confidence interval (CI). Overall, SMD and RR with 95% CI were estimated with Mantel-Haenszel fixed-effects ([@b20-etm-0-0-7129]) or DerSimonian-Laird random-effects models ([@b21-etm-0-0-7129]). When it was confirmed that there was no heterogeneity, pooled SMD and RR were calculated according to the Mantel-Haenszel fixed-effects model (P\>0.05 or I^2^\<50%). If there was evidence of heterogeneity, pooled SMD and RR were calculated according to the DerSimonian-Laird random-effects model (P\<0.05 or I^2^\>50%). Begg\'s funnel plots were drawn to evaluate publication bias.

Results
=======

### Study selection and characteristics

A total of 2,135 records of trials for the treatment of PD-CIND, PDD or DLB were retrieved from the Cochrane Library, Pubmed, Embase and Web of Science. Of these studies, a large quantity was not relevant, including studies regarding other diseases or interventions, or duplications. A total of 237 records were considered suitable after screening the titles and abstracts. Finally, of the 237 full-text articles, only 15 trials \[six donepezil ([@b22-etm-0-0-7129]--[@b27-etm-0-0-7129]), five rivastigmine ([@b10-etm-0-0-7129],[@b28-etm-0-0-7129]--[@b31-etm-0-0-7129]) and four memantine trials ([@b32-etm-0-0-7129]--[@b35-etm-0-0-7129])\] were included in the present meta-analysis. The flow chart for the selection of studies is presented in [Fig. 1](#f1-etm-0-0-7129){ref-type="fig"} and the details of each included article are presented in [Table I](#tI-etm-0-0-7129){ref-type="table"}. The methodological quality of all studies evaluated using the Cochrane risk of bias criteria is provided in [Fig. 2](#f2-etm-0-0-7129){ref-type="fig"}.

Efficacy outcomes
-----------------

### Global cognitive function

Of the trials included, 12 ([@b10-etm-0-0-7129],[@b22-etm-0-0-7129]--[@b30-etm-0-0-7129],[@b32-etm-0-0-7129],[@b33-etm-0-0-7129]) evaluated cognitive function using the MMSE and MoCA ([Fig. 3](#f3-etm-0-0-7129){ref-type="fig"}). The standard mean difference in participants who received cholinesterase inhibitors or memantine vs. placebo was 0.46 (95% CI: 0.36--0.55; P\<0.00001), suggesting significant benefits. Regarding different subgroups, benefits were determined for donepezil in DLB (SMD=0.63; 95% CI: 0.42--0.84; P\<0.00001) and in PDD (SMD=0.51; 95% CI: 0.36--0.66; P\<0.00001), and for rivastigmine in PDD (SMD=0.45; 95% CI: 0.28--0.62; P\<0.00001), but not for rivastigmine in DLB or memantine in either DLB or PDD.

### Cognitive domains

A total of seven trials ([@b23-etm-0-0-7129],[@b25-etm-0-0-7129]--[@b27-etm-0-0-7129],[@b29-etm-0-0-7129],[@b31-etm-0-0-7129],[@b33-etm-0-0-7129]) examined the cognitive domains of attention, processing speed and executive functions ([Fig. 4A](#f4-etm-0-0-7129){ref-type="fig"}). The results of the meta-analysis indicated that cholinesterase inhibitors and memantine provided significant benefits compared with placebo (MD=1.19; 95% CI: 0.65--1.73; P\<0.0001). Furthermore, three trials ([@b23-etm-0-0-7129],[@b26-etm-0-0-7129],[@b33-etm-0-0-7129]) examined the cognitive domain of memory ([Fig. 4B](#f4-etm-0-0-7129){ref-type="fig"}). The meta-analysis revealed that treatment with cholinesterase inhibitors achieved a significant improvement in patients compared with placebo (MD=0.24; 95% CI: 0.11--0.37; P=0.0003). In addition, three trials ([@b26-etm-0-0-7129],[@b29-etm-0-0-7129],[@b33-etm-0-0-7129]) examined visuospatial cognition ([Fig. 4C](#f4-etm-0-0-7129){ref-type="fig"}). The results indicated that cholinesterase inhibitors did not improve visuospatial function when compared with the placebo (MD=0.13; 95% CI: −0.45--0.71; P=0.65). Finally, four trials ([@b23-etm-0-0-7129],[@b25-etm-0-0-7129],[@b29-etm-0-0-7129],[@b33-etm-0-0-7129]) examined the cognitive domain of language ([Fig. 4D](#f4-etm-0-0-7129){ref-type="fig"}). The meta-analysis revealed that cholinesterase inhibitors had a significant effect in patients compared with placebo (MD=1.44; 95% CI: 0.34--2.53; P=0.01).

### Global impression

A total of seven trials ([@b23-etm-0-0-7129]--[@b25-etm-0-0-7129],[@b29-etm-0-0-7129],[@b32-etm-0-0-7129],[@b34-etm-0-0-7129],[@b35-etm-0-0-7129]) examined the subjects on the Clinician\'s Global Impression of Change (CGIC) scale. As indicated in the forest plot in [Fig. 5](#f5-etm-0-0-7129){ref-type="fig"}, significant improvements in participants treated with the drugs compared with the placebo were revealed (RR=1.29; 95% CI: 1.15--1.45; P\<0.0001). Furthermore, in the following subgroups, significant benefits compared with the placebo group were identified: DLB treated with donepezil 3 mg (RR=2.06; 95% CI: 1.18--3.60), donepezil 5 mg (RR=2.13; 95% CI: 1.22--3.70) and donepezil 10 mg (RR=1.93; 95% CI: 1.08--3.43); and PDD treated with rivastigmine (RR=1.37; 95% CI: 1.05--1.79). However, no significant benefits were determined for donepezil in PDD, memantine in PDD and DLB.

### Behavioral symptoms

Altered Neuropsychiatric Inventory (NPI) scores were determined by nine trials ([@b22-etm-0-0-7129],[@b23-etm-0-0-7129],[@b25-etm-0-0-7129],[@b26-etm-0-0-7129],[@b28-etm-0-0-7129],[@b29-etm-0-0-7129],[@b31-etm-0-0-7129],[@b32-etm-0-0-7129],[@b34-etm-0-0-7129]). As presented in [Fig. 6](#f6-etm-0-0-7129){ref-type="fig"}, meta-analysis revealed a significant effect on NPI-10 among all studies \[MD=−1.73; 95% CI: -(2.84--0.62); P=0.002\].

### Motor function

A total of 10 trials assessed motor function ([@b10-etm-0-0-7129],[@b22-etm-0-0-7129]--[@b24-etm-0-0-7129],[@b26-etm-0-0-7129],[@b27-etm-0-0-7129],[@b30-etm-0-0-7129]--[@b32-etm-0-0-7129],[@b34-etm-0-0-7129]). Compared with the placebo, patients treated with cholinesterase inhibitors and memantine exhibited improvements in motor function ([Fig. 7](#f7-etm-0-0-7129){ref-type="fig"}). The results of the meta-analysis suggested a significant effect on patients treated with drugs compared with placebo \[MD=−1.38; 95% CI: -(1.96--0.79); P\<0.00001\]. However, only rivastigmine in PDD provided a significant benefit \[MD=−2.32; 95% CI: -(3.09--1.55); P\<0.00001\], while donepezil in PDD or DLB, rivastigmine in DLB, and memantine in PDD and/or DLB did not. Furthermore, a subgroup analysis revealed that the dose of donepezil had no significant effect in improving DLB.

### Falling

A considerable number of patients experience falls as a complication of PDD and five of the trials included ([@b10-etm-0-0-7129],[@b25-etm-0-0-7129],[@b29-etm-0-0-7129],[@b32-etm-0-0-7129],[@b35-etm-0-0-7129]) reported on the quantity of falling. As presented in [Fig. 8](#f8-etm-0-0-7129){ref-type="fig"}, the meta-analysis revealed that cholinesterase inhibitors and memantine did not significantly reduce falling compared with the placebo (RR=0.74; 95% CI: 0.51--1.08; P=0.12), thereby demonstrating that treatment with the drugs did not significantly prevent falls.

### Adverse events

Adverse events were inconsistently mentioned and reported by 13 trials ([@b10-etm-0-0-7129],[@b22-etm-0-0-7129]--[@b28-etm-0-0-7129],[@b30-etm-0-0-7129]--[@b32-etm-0-0-7129],[@b34-etm-0-0-7129],[@b35-etm-0-0-7129]). The common adverse events were cholinergic in nature (nausea, vomiting), aggravation of Parkinson and psychiatric symptoms (tremor, fall, somnolence, insomnia, hallucinations), urinary tract infection and respiratory tract infection; however, most adverse events were mild or moderate. As presented in [Fig. 9](#f9-etm-0-0-7129){ref-type="fig"}, the results of the meta-analysis revealed more adverse events in the treatment groups compared with those in the placebo group (RR=1.09; 95% CI: 1.04--1.16; P=0.001). However, among the subgroups, only the rivastigmine group experienced significantly more adverse events compared the placebo group (RR=1.18; 95% CI: 1.08--1.29; P=0.0001; data not shown). Donepezil and memantine did not produce any significant adverse events compared with the placebo.

### Publication bias

The publication bias regarding cognitive and motor function was determined by drawing Begg\'s funnel plots ([Fig. 10A and B](#f10-etm-0-0-7129){ref-type="fig"}). The shape of the funnel plots exhibited no obvious asymmetry, which indicated the absence of significant heterogeneity between these selected studies, and the pooled results were not influenced by publication bias.

### Sensitivity analysis

A sensitivity analysis was conducted to assess the stability of the results by sequential removal of individual studies. The heterogeneity (I^2^=75%) in global cognitive function is shown in [Fig. 3](#f3-etm-0-0-7129){ref-type="fig"}, the study by Li *et al* ([@b10-etm-0-0-7129]) did not provide the mean differences with SDs, but rather electing to report the mean and SDs prior to and following treatment, which may have resulted in data conversion-associated errors. Following the exclusion of the study, the analysis results did not change. In [Fig. 4A](#f4-etm-0-0-7129){ref-type="fig"}, numerous trials that examined cognitive domains were then assessed (I^2^=78%), it was found that the results did not change following the sequential removal of individual studies. The authors of the current study estimated that there was variability in measurement precision.

Discussion
==========

The present meta-analysis assessed the efficacy and safety of cholinesterase inhibitors and memantine in the treatment of CIND-PD, PDD and DLB, which contained four new more articles than a previous meta-analysis ([@b9-etm-0-0-7129]). To the best of our knowledge, the present study was the first meta-analysis to report on the effect of cholinesterase inhibitors and memantine in subjects with CIND-PD, PDD and DLB, including cognitive domains (attention, processing speed, executive functions, memory, visuospatial cognition and language). The results indicated that cholinesterase inhibitors had beneficial effects on attention, processing speed, executive functions, memory and language, but did not improve visuospatial cognition when compared with the placebo. Furthermore, memantine was revealed to improve attention, processing speed and executive functions. However, cholinesterase inhibitors and memantine did not significantly reduce falling. Compared with the placebo, more adverse events occurred in the pooled cholinesterase inhibitors and memantine group than in the placebo group. However, a subgroup analysis indicated that only the rivastigmine group experienced significantly more adverse events than the placebo group, while donepezil and memantine did not produce any significant adverse events.

Consistent with the results of previous meta-analyses, the present study indicated that donepezil was beneficial for DLB regarding cognitive function and global impression, but not in any other aspects. Recently published secondary analyses of donepezil suggest statistically significant advantages of donepezil over placebo regarding aspects of Behavioural and Psychological Symptoms of Dementia (BPSD), improvement of cognitive function and visual hallucinations ([@b36-etm-0-0-7129]--[@b38-etm-0-0-7129]). Manabe *et al* ([@b36-etm-0-0-7129]) observed that 10 mg donepezil improved BPSD in DLB. Mori *et al* ([@b37-etm-0-0-7129]) reported that increasing the dose of donepezil from 5 to 10 mg enhanced the effect in improving cognitive function in DLB with little influence on the safety. Ukai *et al* ([@b38-etm-0-0-7129]) reported that donepezil was highly effective against visual hallucinations in DLB.

Galanthamine is another cholinesterase inhibitor. To date, the potential benefits of galanthamine have remained insufficiently demonstrated, except for an open-label trial. Litvinenko *et al* ([@b39-etm-0-0-7129]) reported that galanthamine improved cognitive function, behavioral symptoms, daily activity and the number of falls. Galanthamine treatment was not associated with any significant adverse events when compared with the placebo.

The results of the present meta-analysis revealed that memantine only had a minor side effect on the participants; however, this is in contrast to the meta-analysis by Matsunaga *et al* ([@b6-etm-0-0-7129]). This discrepancy may have been due to the fact that the analysis of the present study included two further trials, which may have provided more accurate results. Larsson *et al* ([@b40-etm-0-0-7129]) reported that memantine decreases the probable rapid eye movement sleep behavioral disorder in patients with DLB and PDD.

Safety is as important as the efficacy of the interventions in clinical studies. All of the three drugs assessed in the present study adhered to certain safety standards; however, rivastigmine produced more adverse events compared with those in the placebo group. Of note, donepezil and memantine did not produce any significant adverse events compared with the placebo. None of the drugs improved or aggravated the symptoms of Parkinsonism compared with the placebo. Emre *et al* ([@b41-etm-0-0-7129]) reported that in a 76-week, prospective, open-label, randomized study in PDD patients aged 50 to 85 years, rivastigmine exhibited long-term safety.

Of note, the present meta-analysis had several limitations. First, even though 15 trials were included, the number of participants was small, and the results may not sufficiently allow for making any final conclusions. Furthermore, a complete evaluation of all interventions applied was impossible due to a lack of data. In addition, most of the trials included were relatively short, and more long-term trials with relatively longer follow-up periods similar to that by Li *et al* ([@b10-etm-0-0-7129]) lasting 12 months, are required for further evaluation. In addition, in the cognitive domains analysis with I^2^=78%, variation in at times overlapping interventions, heterogeneity in outcomes assessed and low number of controls were of greatest concern. The studies examined were performed across multiple countries with instruments that may appear to be similar, prima facie, but may substantially differ in how they sequentially remove individual studies ([@b42-etm-0-0-7129]). The authors of the current study combined different doses of the same drug for analysis, thus this may lead to biased results; this must be taken into consideration and eliminated in future studies.

In conclusion, cholinesterase inhibitors provide a benefit not only regarding global cognitive function, CGIC and behavioral symptoms, but also in cognitive domains. Memantine treatment results in a significant improvement in attention, processing speed and executive functions according to sensitivity analysis. However, cholinesterase inhibitors and memantine do not significantly reduce falling. Finally, cholinesterase inhibitors and memantine are associated with good safety outcomes, with only the rivastigmine group exhibiting significant adverse events compared with the placebo group. However, considering the limitations of the present study, the results may not sufficiently support the use of cholinesterase inhibitors and memantine as treatments for CIND-PD, PDD and DLB. Further clinical trials on a larger scale are imperative to better assess the efficacy and safety of cholinesterase inhibitors and memantine in CIND-PD, PDD and DLB.
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![Forest plot of the meta-analysis of cognitive outcomes determined by Mini-Mental State Examination and Montreal Cognitive Assessment for various drugs and doses. The risk ratio is presented as green squares, with the horizontal lines indicating the confidence interval. Combined results for all studies are presented as black diamonds. CI, confidence interval; IV, inverse variance; SD, standard deviation; df, degrees of freedom; PDD, Parkinson\'s disease with dementia; DLB, dementia with Lewy bodies.](etm-17-03-1611-g02){#f3-etm-0-0-7129}

###### 

Forest plot of the meta-analysis for the cognitive domains of (A) attention, processing speed and executive functions, (B) memory for donepezil, rivastigmine and memantine, and (C) visuospatial cognition. The risk ratio is presented as green squares, with the horizontal lines indicating the confidence interval. Combined results for all studies are presented as black diamonds. Forest plot of the meta-analysis for the cognitive domain of (D) language for donepezil and rivastigmine. The risk ratio is presented as green squares, with the horizontal lines indicating the confidence interval. Combined results for all studies are presented as black diamonds. CI, confidence interval; IV, inverse variance; SD, standard deviation; df, degrees of freedom; VPTA, Visual Perception Test for Agnosia; AQT, A Quick Test of Cognitive Speed; WMS-R, Wechsler Memory Scale-Revised; BTA, Brief Test of Attention; DRS, Dementia Rating Scale; TMT, Trial Making Test; DSST, Digit Symbol Substitution Test; HVLT-R, Hopkins Verbal Learning Test-Revised.
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![Forest plot of the meta-analysis of Clinical Global Impression of Change by drug and dose. The risk ratio is presented as green squares, with the horizontal lines indicating the confidence interval. Combined results for all studies are presented as black diamonds. CI, confidence interval; M-H, Mantel-Haentzel; df, degrees of freedom; PDD, Parkinson\'s disease with dementia; DLB, dementia with Lewy bodies.](etm-17-03-1611-g06){#f5-etm-0-0-7129}

![Forest plot of the meta-analysis of behavioral symptoms according to the 10-Item Neuropsychiatric Inventory by drug and dose. The risk ratio is presented as green squares, with the horizontal lines indicating the confidence interval. Combined results for all studies are presented as black diamonds. CI, confidence interval; IV, inverse variance; SD, standard deviation; df, degrees of freedom; PDD, Parkinson\'s disease with dementia; DLB, dementia with Lewy bodies.](etm-17-03-1611-g07){#f6-etm-0-0-7129}

![Forest plot of the meta-analysis of motor function on the Unified Parkinson\'s Disease Rating Scale-motor by drug and dose. The risk ratio is presented as green squares, with the horizontal lines indicating the confidence interval. Combined results for all studies are presented as black diamonds. CI, confidence interval; IV, inverse variance; SD, standard deviation; df, degrees of freedom; PDD, Parkinson\'s disease with dementia; DLB, dementia with Lewy bodies.](etm-17-03-1611-g08){#f7-etm-0-0-7129}

![Forest plot of the meta-analysis of falling by drug and dose for Parkinson\'s disease with dementia and cognitive impairment in Parkinson\'s disease. The risk ratio is presented as blue squares, with the horizontal lines indicating the confidence interval. Combined results for all studies are presented as black diamonds. CI, confidence interval; M-H, Mantel-Haentzel; df, degrees of freedom.](etm-17-03-1611-g09){#f8-etm-0-0-7129}
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![Funnel plot of (A) cognition and (B) motor function. PDD, Parkinson\'s disease with dementia; DLB, dementia with Lewy bodies; SE, standard error; SMD, standard mean difference; MD, mean difference.](etm-17-03-1611-g11){#f10-etm-0-0-7129}

###### 

Summary of studies included in the present meta-analysis.

  First author (year)   Total (n)   Condition     Duration/design                                  Drug        Age (mean ± SD)                                                                                                       Males (%)                                                                                                   n of each group   Dose (mg/day)            Outcomes                                                   (Refs.)
  --------------------- ----------- ------------- ------------------------------------------------ ----------- --------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------- ------------------------ ---------------------------------------------------------- -----------------------
  Aarsland (2002)       14          CIND-PD       10 weeks                                         DON         71±3.9                                                                                                                92                                                                                                            12              10 (flexible dose)       MMSE, CIBIC-plus,                                          ([@b24-etm-0-0-7129])
                                                  (crossover design)                                                                                                                                                                                                                                                                                                                        UPDRS-motor, NPI                                           
  Ravina (2005)         22          PDD           10 weeks                                         DON         DON/PLA: 75.0±9.8                                                                                                     DON/PLA: 100                                                                                                  19              10 (flexible dose)       MMSE, CGI-CADAS-cog,                                       ([@b27-etm-0-0-7129])
                                                  (crossover design)                               PLA         PLA/DON: 72.1±8.1                                                                                                     PLA/DON: 60                                                                                                   19                                       MDRS, BPRS, UPDRS-motor                                    
  Mori (2012)           140         DLB           12 weeks                                         DON 10 mg   DON 10 mg: 78.6±6.1                                                                                                   DON 10 mg: 11.1                                                                                               37              10 (flexible dose)       MMSE, WMS-R, WAIS-III,                                     ([@b23-etm-0-0-7129])
                                                                                                   DON 5 mg    DON 5 mg: 77.9±6.8                                                                                                    DON 5 mg: 50.0                                                                                                33              5 (flexible dose)        NPI, VF, VPTA, UPDRS-motor                                 
                                                                                                   DON 3 mg    DON 3 mg: 79.6±4.5                                                                                                    DON 3 mg: 48.6                                                                                                35              3 (flexible dose)                                                                   
                                                                                                   PLA         PLA: 78.6±4.7                                                                                                         PLA: 28.1                                                                                                     35              PLA                                                                                 
  Ikeda (2015)          142         DLB           12 weeks                                         DON 10 mg   DON 10 mg: 77.7±6.8                                                                                                   DON 10 mg: 42.9                                                                                               49              10 (fixed dose)          MMSE, NPI, UPDRS-motor                                     ([@b22-etm-0-0-7129])
                                                                                                   DON 5 mg    DON 5 mg: 78.8±5.1                                                                                                    DON 5 mg: 44.4                                                                                                47              5 (fixed dose)                                                                      
                                                                                                   PLA         PLA: 77.2±6.1                                                                                                         PLA: 38.6                                                                                                     46                                                                                                  
  Dubois (2012)         550         PDD           24 weeks                                         DON 10 mg   DON 10 mg: 70.8±7.46                                                                                                  DON 10 mg: 75                                                                                               182               10 (fixed dose)          CIBIC-plus, MMSE, VF, BTA,                                 ([@b25-etm-0-0-7129])
                                                                                                   DON 5 mg    DON 5 mg: 72.0±6.83                                                                                                   DON 5 mg: 65                                                                                                195               5 (fixed dose)           ADAS-cog, NPI                                              
                                                                                                   PLA         PLA: 72.9±6.48                                                                                                        PLA: 65                                                                                                     173               PLA                                                                                 
  McKeith (2000)        120         DLB           20 weeks                                         RIV         RIV: 73.9±6.5                                                                                                         RIV: 52.5                                                                                                     59              12 (flexible dose)       NPI, CGC-plus, MMSE                                        ([@b28-etm-0-0-7129])
                                                                                                   PLA         PLA: 73.9±6.4                                                                                                         PLA: 60.7                                                                                                     61                                                                                                  
  Emre (2010)           199         DLB and PDD   24 weeks                                         MEM         MEM: 74.4±5.8                                                                                                         MEM: 53.1                                                                                                     96              MEM: 20 (fixed dose)     ADCS-CGIC, NPI, UPDRS                                      ([@b34-etm-0-0-7129])
                                                                                                   PLA         PLA: 72.5±7.0                                                                                                         PLA: 57.6                                                                                                     99                                                                                                  
  Leroi (2009)          25          PDD           16 weeks (from                                   MEM         MEM: 76.7±7.8                                                                                                         MEM: 36.4                                                                                                     11              MEM: 20 (fixed)          MMSE, NPI, UPDRS-3, CIBIC-Plus                             ([@b32-etm-0-0-7129])
                                                  17 weeks to 22 weeks: Off drug)                  PLA         PLA: 74.7±7.9                                                                                                         PLA: 4.3                                                                                                      14                                                                                                  
  Leroi (2004)          16          PDD or        18 weeks                                         DON         DON: 66.2±9.3                                                                                                         DON: 85.7                                                                                                     7               10 mg (flexible dose)    Cognitive domains, VMI, NPI,                               ([@b26-etm-0-0-7129])
                                    CIND-PD                                                        PLA         PLA: 70.8±11.8                                                                                                        PLA: 44.4                                                                                                     9                                        UPDRS-ADL, Motor function, Complication of treatment       
  Emre (2004)           541         PDD           24 weeks                                         RIV         RIV: 72.8±6.7                                                                                                         RIV: 64.6                                                                                                   362               12 mg (flexible dose)    ADAS-cog, ADCS-CGIC, NPI-10,                               ([@b29-etm-0-0-7129])
                                                                                                   PLA         PLA: 72.4±6.4                                                                                                         PLA: 65.4                                                                                                   179                                        MMSE, VF, CDT, UPDRS-motor                                 
  Mamikonyan (2015)     28          CIND-PD       10 weeks                                         RIV patch   64.3±8.2                                                                                                              78.6                                                                                                          27              9.5 mg (flexible dose)   ADCS-CGIC, MoCA, PDRS-motor                                ([@b30-etm-0-0-7129])
                                                  (crossover design)                               PLA                                                                                                                                                                                                                                             27                                                                                                  
  Wesnes (2002)         92          DLB           20 weeks                                         RIV         RIV: 73.9±6.5                                                                                                         RIV: 52.5                                                                                                     41              12 mg (flexible dose)    DSST, attention, processing speed,                         ([@b31-etm-0-0-7129])
                                                  (crossover design)                               PLA         PLA: 73.9±6.4                                                                                                         PLA: 60.7                                                                                                     51                                       Stroop Congruent Test, Trails A/B, Word Association Test   
  Li (2015)             81          PD-MCI, PDD   12 months                                        RIV         RIV: 67.5±not clear                                                                                                   RIV: 73.2                                                                                                     41              3 mg (flexible dose)     MoCA, falls                                                ([@b10-etm-0-0-7129])
                                                                                                   PLA clear   PLA: 66.9±not                                                                                                         PLA: 52.5                                                                                                     40                                                                                                  
  Aarsland (2009)       72          PDD, DLB      24 weeks (from 17 weeks to 22 weeks: Off drug)   MEM         MEM: 76.9±6.1                                                                                                         MEM: 79.4                                                                                                   34                20 mg (flexible dose)    CGIC, MMSE, NPI, UPDRS                                     ([@b33-etm-0-0-7129])
                                                                                                   PLA         PLA: 76.2±5.8                                                                                                         PLA: 71.1                                                                                                   38                                                                                                    
  Stubendorff (2014)    75          PDD; DLB      24 weeks                                         MEM         MEM: 73.8±5.5^[a](#tfn1-etm-0-0-7129){ref-type="table-fn"}^, 75.2±5.6^[b](#tfn2-etm-0-0-7129){ref-type="table-fn"}^   MEM: 75^[a](#tfn1-etm-0-0-7129){ref-type="table-fn"}^, 100^[b](#tfn2-etm-0-0-7129){ref-type="table-fn"}^    18 (12/6)         20 mg (flexible dose)    Survival                                                   ([@b35-etm-0-0-7129])
                                                                                                   PLA         PLA: 76.5±4.7^[a](#tfn1-etm-0-0-7129){ref-type="table-fn"}^, 75.6±4.6^[b](#tfn2-etm-0-0-7129){ref-type="table-fn"}^   PLA: 66.7^[a](#tfn1-etm-0-0-7129){ref-type="table-fn"}^, 60^[b](#tfn2-etm-0-0-7129){ref-type="table-fn"}^   14 (9/5)                                                                                              

Subgroup 1

subgroup 2. PDD, Parkinson\'s disease with dementia; DLB, dementia with Lewy bodies; MCI, mild cognitive impairment; PLA, placebo; MEM, memantine; RIV, rivastigmine; CIND-PD, cognitive impairment in Parkinson\'s disease; DON, donepezil; MMSE, Mini Mental State Examination; MoCa, Montreal Cognitive Assessment; CIBIC, Clinician\'s Interview-Based Impression of Change; UPDRS, Unified Parkinson\'s Disease Rating Scale; NPI, Neuropsychiatric Inventory; CGI-CDRCAS, Clinical Global Impression-Cognitive Drug Research Computerized Assessment System; BPRS, Brief Psychosis Rating Scale; MDRS, Mattis Dementia Rating Scale; VF, Verbal Fluency; VMI, develop-mental test of Visual-Motor Integration; VPTA, Visual Perception Test for Agnosia; WAIS-III Wechsler Adult IntelligenceScale; WMS-R, Wechsler Memory Scale-Revised; CDT, clock drawing test; CGC-plus, Clinical Global Change-plus; ADL, Activities of Daily Living; ADCS-CGIC, Alzheimer\'s Disease Cooperative Study-Clinician\'s Global Impression of Change; ADAS-cog, Alzheimer\'s Disease Assessment Scale cognitive subscale; SD, standard deviation; DSST, Digit Symbol Substitution Test; BTA, Brief test of Attention.
